Swiss stocks – Factors to watch on Oct 25

ZURICH, Oct 25 (BestGrowthStock) – Swiss stocks are set to rise on
Monday, in line with leading European benchmark indexes look set
to rally after the Group of 20 major economies’ agreement not to
pursue competitive currency devaluations.

The Swiss blue-chip index SMI (.SSMI: ) was indicated to rise
40 points at 6,518 points, premarket data provided by bank
Clariden Leu showed.(CLPRE: )

The following are some of the main factors expected to
affect Swiss stocks on Monday:

NOVARTIS (NOVN.VX: )

Swiss drugmaker Novartis AG (NOVN.VX: ) wants to file its
meningitis vaccine Menveo for use in small infants in the United
States and Europe after a late-stage study with children of this
age group was successful

For related news, click on [NOVN.VX]

UBS (UBSN.VX: )

The U.S. Department of Justice is seeking to dismiss a
criminal prosecution against UBS AG that led to the Swiss bank
paying a $780 million penalty and admitting it helped wealthy
U.S. clients evade taxes.

For related news click on [UBSN.VX]

NESTLE (NESN.VX: )

Nestle SA, the world’s biggest food company, plans to expand
in the bottled tea and frozen foods markets in the United
States, said Kim Jeffery, chief executive of Nestle Waters North
America on Friday.

For related news, click on [NESN.VX]

ECONOMY [M-CH]

* Swiss Finance Minister Hans-Rudolf Merz will sign a tax
deal with Germany on Thursday critical to the future of
Switzerland’s $2 trillion wealth management industry, Swiss news
agency SDA reported on Sunday. [ID:LDE69N0E1]

COMPANY STATEMENTS [CNR-CH]

* Lonza (LONN.VX: ) and BD Diagnostics collaborate to
commercialize the Lonza microCompass molecular assays on the BD
Max System. [LONN.VX]

* Alcon independent director committee notes that Daniel
Vasella, chairman of Novartis, replaced Cary Rayment as chairman
of the Alcon board of directors. [NOVN.VX]

* Barry Callebaut (BARN.S: ) restated previous year’s figures
due to first-time application of IFRS 8. [BARN.S]

* Santhera (SANN.S: ) regains full rights to fipamezole in
North America. [SANN.S]

* Charles Voegele (VCH.S: ) said Karin Bertschinger, vice
president group human resources, and Daniel B